Janone selects regulatory partner for phase 2b trial as investigational plan is prepared for fda filing

Las vegas, june 22, 2021 /prnewswire/ -- janone inc. (nasdaq: jan), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of avania as its regulatory partner in the upcoming planned phase 2b trial of lead product candidate jan101 for treating peripheral artery disease (pad). avania will manage all regulatory operations associated with trial preparedness and execution including ensuring compliance with the fda's requirements for investigational practices and managing correspondence with the fda on janone's behalf throughout the duration of the trial.
JAN Ratings Summary
JAN Quant Ranking